Categories Earnings, Industrials
737 Max grounding in focus as American Airlines prepares for Q1 earnings
Closely following the heels of peers Delta Air Lines (NYSE: DAL) , United Airlines (NASDAQ: UAL) and Southwest Airlines (NYSE: LUV), American Airlines (NASDAQ: AAL) is scheduled to report first-quarter earnings results on Friday, April 26, before the opening bell.
The world’s largest airline by fleet size is expected to report a 2.6% growth in revenue to $10.67 billion during the quarter, when operations were marred by the grounding of Boeing 737 Max jets following the crash of Ethiopian Airlines Flight 302 over Addis Ababa. The grounding had forced American Airlines to cancel as many as 1,200 flights during the first quarter.
Earlier this month, the company had slashed its projection on total revenue per available seat mile (TRASM) to 0-1%. Previously, Q1 TRASM was projected at flat to 2%.
The Fort Worth, Texas-based firm also cut down its guidance on consolidated cost per available seat mile to approximately 3%.
Separately, the price of jet fuel increased over 30% in the first quarter, which is expected to weigh on the profits.
On the flip side, AAL bulls are pinning their hopes on the company’s impressive history of beating street estimates. The airline also reportedly witnessed a decent growth in traffic since March, which could offset some of the aforementioned headwinds.
READ: FACEBOOK REPORTS 26% JUMP IN Q1 REVENUE
AAL shares have gained 5.2% since the beginning of this year. The stock has a 12-month average price target of $45.57, suggesting a 33% upside from the last close.
Earlier this week, Southwest Airlines reported earnings that surpassed market estimates, though the market wasn’t impressed with the results. Last week, United Continental Holdings, the parent of United Airlines, beat consensus earnings target, while its revenue came in line with the estimates.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on